Literature DB >> 22538476

Antimalarial efficacy of a quantified extract of Nauclea pobeguinii stem bark in human adult volunteers with diagnosed uncomplicated falciparum malaria. Part 2: a clinical phase IIB trial.

Kahunu Mesia1, Lutete Tona, Ma Miezi Mampunza, Nsengi Ntamabyaliro, Tsobo Muanda, Tamfum Muyembe, Tshinanu Musuamba, Tony Mets, Kanyanga Cimanga, Jozef Totté, Luc Pieters, Arnold J Vlietinck.   

Abstract

According to the promising results of the Phase I and Phase IIA clinical trials with the herbal medicinal product PR 259 CT1 consisting of an 80 % ethanolic extract of the stem bark of Nauclea pobeguinii containing 5.6 % strictosamide, a Phase IIB study was conducted as a single blind prospective trial in 65 patients with proven Plasmodium falciparum malaria to evaluate the effectiveness and safety of this herbal drug. The study was carried out simultaneously using an artesunate-amodiaquine combination (Coarsucam®) as a positive control. This combination is the standard first-line treatment for uncomplicated malaria recommended by the National Programme of Malaria Control in the Democratic Republic of Congo (DR Congo). With regard to PR 259 CT1, patients were treated with a drug regimen of two 500-mg capsules three times daily for three days in the inpatient clinic, followed by out-patient treatment of one 500-mg capsule three times daily during the next four days; the positive control group received two tablets containing 100 mg artesunate and 270 mg amodiaquine (fixed-dose) once daily during three consecutive days. Antimalarial responses were evaluated according to the WHO 2003 guideline for a 14-day test. The results from the physical and laboratory examinations did not show any significant changes in values of vital signs, ECG, biochemical, and haematological parameters. The study showed a significant decreased parasitaemia in patients treated with PR 29 CT1 and artesunate-amodiaquine with adequate clinical parasitological responses (APCR) at day 14 of 87.9 and 96.9 %, respectively. The former product was better tolerated than the latter since more side effects were observed for the artesunate-amodiaquine combination. These results indicated that PR 259 CT1 can be considered as a promising candidate for the development of a herbal medicine for the treatment of uncomplicated falciparum malaria. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22538476     DOI: 10.1055/s-0031-1298488

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  8 in total

1.  Antimalarial Use of Malagasy Plants is Poorly Correlated with Performance in Antimalarial Bioassays.

Authors:  Wendy L Applequist; Michel Ratsimbason; Alyse Kuhlman; Stephan Rakotonandrasana; Vincent Rasamison; David G I Kingston
Journal:  Econ Bot       Date:  2017-03-31       Impact factor: 1.731

Review 2.  New insight-guided approaches to detect, cure, prevent and eliminate malaria.

Authors:  Sushil Kumar; Renu Kumari; Richa Pandey
Journal:  Protoplasma       Date:  2014-10-17       Impact factor: 3.356

Review 3.  Antimalarial drug discovery - approaches and progress towards new medicines.

Authors:  Erika L Flannery; Arnab K Chatterjee; Elizabeth A Winzeler
Journal:  Nat Rev Microbiol       Date:  2013-11-11       Impact factor: 60.633

Review 4.  Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine With COVID-19 in Focus: A Nigerian Perspective.

Authors:  Alfred Francis Attah; Adeshola Adebayo Fagbemi; Olujide Olubiyi; Hannah Dada-Adegbola; Akinseinde Oluwadotun; Anthony Elujoba; Chinedum Peace Babalola
Journal:  Front Pharmacol       Date:  2021-04-26       Impact factor: 5.810

5.  Antidiabetic potential of two medicinal plants used in Gabonese folk medicine.

Authors:  Huguette Agnaniet; Elvis Jolinom Mbot; Ousmane Keita; Jean-Alain Fehrentz; Anita Ankli; Audrey Gallud; Marcel Garcia; Magali Gary-Bobo; Jacques Lebibi; Thierry Cresteil; Chantal Menut
Journal:  BMC Complement Altern Med       Date:  2016-02-22       Impact factor: 3.659

6.  Phytochemical analysis with free radical scavenging, nitric oxide inhibition and antiproliferative activity of Sarcocephalus pobeguinii extracts.

Authors:  Emmanuel Mfotie Njoya; Aristide Mfifen Munvera; Pierre Mkounga; Augustin Ephrem Nkengfack; Lyndy Joy McGaw
Journal:  BMC Complement Altern Med       Date:  2017-04-04       Impact factor: 3.659

7.  Antibacterial and antibiotic-resistance modifying activity of the extracts and compounds from Nauclea pobeguinii against Gram-negative multi-drug resistant phenotypes.

Authors:  Jackson A Seukep; Louis P Sandjo; Bonaventure T Ngadjui; Victor Kuete
Journal:  BMC Complement Altern Med       Date:  2016-07-07       Impact factor: 3.659

8.  A Phase II Pilot Trial to Evaluate CoBaT-Y017 Safety and Efficacy against Uncomplicated Falciparum Malaria versus Artemether-Lumefantrine in Benin Subjects.

Authors:  Adrien N Noudjiegbe; Femi N Alikekere; Henri Tchehouenou; Yéman Langa; Daniel S Ota; Jean-Eudes Degbelo; Aurel C E Allabi
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-17       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.